Global Pulmonary Arterial Hypertension (PAH) Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

The report analyzes and forecasts the pulmonary arterial hypertension (PAH) market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

Increasing prevalence of Pulmonary Arterial Hypertension (PAH) and government support for the development of orphan drugs are fueling the growth.

The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, the occurrence of this disorder has intensified due to the risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Presence of a large geriatric population, with lower levels of immunity and prone to PAH and associated diseases, is a high impact-rendering driver for the PAH market. Though the beginning age for PAH is 45 years, it is often observed to occur in the population over 60 years of age.

Government initiatives, such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are also anticipated to support market growth. These are the two most vital acts that promote the ethical usage and distribution of orphan drugs. Development of orphan drugs is promoted by the National Organization of Rare Disorders and have a smaller market share.

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global pulmonary arterial hypertension (PAH) market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the pulmonary arterial hypertension (PAH) market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of pulmonary arterial hypertension (PAH) market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

The report has analyzed few of the leading companies in the market. Actelion Pharmaceuticals Ltd., Gilead Sciences Inc., Pfizer Inc., GlaxoSmithKline Plc., Novartis International AG, Bayer HealthCare, and United Therapeutics Corp are few prominent companies in the global pulmonary arterial hypertension market.

Segments Covered in the Report:

Drug Class Outlook (Revenue, USD Million, 2015 - 2026)

Prostacyclin & Prostacyclin Analogs

SGC Stimulators

ERA

PDE-5

Regional Outlook (Revenue, USD Million, 2015 - 2026)

North America

Europe

Asia Pacific

Latin America

Middle East and Africa (MEA)

Reasons to Purchase this Report:

- Estimates 2019-2026 pulmonary arterial hypertension (PAH) market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

• To analyze and study the global pulmonary arterial hypertension (PAH) capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026);
• Focuses on the key pulmonary arterial hypertension (PAH) manufacturers, to study the capacity, production, value, market share and development plans in future.
• Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
• To define, describe and forecast the market by type, application and region.
• To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
• To identify significant trends and factors driving or inhibiting the market growth.
• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
• To strategically profile the key players and comprehensively analyze their growth strategies.